Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-Center, Safety and Pharmacokinetic Bridging Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor with Disposable Adhesive Ring in Normal and Renal Compromised Subjects for the Evaluation of Kidney Function

Next Previous
Trial Profile

An Open Label, Multi-Center, Safety and Pharmacokinetic Bridging Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor with Disposable Adhesive Ring in Normal and Renal Compromised Subjects for the Evaluation of Kidney Function

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relmapirazin (Primary)
  • Indications Acute kidney injury; Kidney disorders
  • Focus Pharmacokinetics; Registrational
  • Sponsors MediBeacon

Most Recent Events

  • 25 Nov 2024 Status changed from active, no longer recruiting to completed.
  • 25 Jun 2024 Status changed from recruiting to active, no longer recruiting.
  • 25 Jun 2024 Planned End Date changed from 1 Apr 2024 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top